Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.63 | N/A | +41.74% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.63 | N/A | +41.74% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on the company's performance. However, the lack of specific revenue guidance raised some concerns.
Management highlighted strong performance in key areas despite not providing specific revenue figures.
They expressed confidence in the company's long-term strategy and growth potential.
Ligand Pharmaceuticals reported a strong EPS that exceeded expectations, but the stock fell by 3.64% in reaction. Investors may be concerned about the absence of revenue figures and future guidance, which could lead to uncertainty about the company's growth trajectory. The mixed results may prompt further scrutiny from analysts and investors in the coming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SOUTHERN COPPER CORP
Jul 26, 2021